No Link Between Anti-Smoking Drugs, Mental Health Issues: Study
Meds like Chantix and Wellbutrin may be safer to use than smokers often realize, research suggests (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 22, 2016 Category: Psychiatry Authors: webmaster at doctorslounge.com Tags: Pharmacy, Psychiatry, Preventive Medicine, News, Source Type: news
No Link Between Anti-Smoking Drugs, Mental Health Issues: Study
FRIDAY, April 22, 2016 -- The anti-smoking drugs Chantix (varenicline) and Wellbutrin (bupropion) don't appear to raise the risk of serious mental health disorders such as depression, anxiety and suicidal thoughts, a new study suggests.
"Clinical... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 22, 2016 Category: Journals (General) Source Type: news
The Lancet: Smoking cessation medications do not appear to increase risk of neuropsychiatric side effects, study finds
(The Lancet) The smoking cessation medications varenicline and bupropion do not appear to increase the incidence of serious neuropsychiatric side effects compared to placebo, according to a study published in The Lancet today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2016 Category: Global & Universal Source Type: news
Smoking cessation drugs do not elevate risk of serious neuropsychiatric adverse effects
(University of California - San Diego) Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the US) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2016 Category: Global & Universal Source Type: news
One antidepressant shown to control weight during 2-year study
Bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss, new research indicates. Previously, researchers linked depression to obesity--and most antidepressant medications to weight gain. The new study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 20, 2016 Category: Science Source Type: news
One antidepressant shown to control weight during 2-year study
(Group Health Research Institute) Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss. Previously, Group Health researchers linked depression to obesity--and most antidepressant medications to weight gain. The new study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 19, 2016 Category: Global & Universal Source Type: news
8 Things Every Woman Should Know About Her Libido
By Hallie Levine Here today, gone tomorrow--your libido can be puzzling, to say the least. But that ebb and flow is completely natural, says Lauren Streicher, MD, clinical associate professor of obstetrics and gynecology at Northwestern Memorial Hospital in Chicago: "All women go through periods when they feel especially frisky, as well as times when they just seem to have lost their mojo." Read on to learn about the many reasons your libido may come and go, and how to find it when you miss it. Curious about aphrodisiacs? We've got those too, from strawberries to Savasana. RELATED: 9 Things Every Woman Must Know About He...
Source: Healthy Living - The Huffington Post - March 28, 2016 Category: Consumer Health News Source Type: news
Your NEJM Group Today: Flint's Water Crisis, Naltrexone-Bupropion's CV Risk Unknown, Maine Hospitalist Opportunity (FREE)
By the Editors
NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 23, 2016 Category: Primary Care Source Type: news
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets
Takeda Moves to Strengthen Focus on Recent Launches
SAN DIEGO and DEERFIELD, Ill., and OSAKA, Japan, March 15, 2016 -- (Healthcare Sales & Marketing Network) -- Ore... Biopharmaceuticals, AcquisitionsOrexigen Therapeutics, Takeda Pharmaceutical, CONTRAVE, naltrexone, bupropion (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 15, 2016 Category: Pharmaceuticals Source Type: news
No LIGHT shed on CV safety of naltrexone-bupropion
The cardiovascular risks of the weight-loss combination drug naltrexone-bupropion are still uncertain, because the FDA-mandated safety trial, LIGHT, was terminated prematurely due to the sponsoring... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 8, 2016 Category: Endocrinology Source Type: news
Saturday with SMACC: Ho v Bellezzo debate — ECMO is a step too far
One of my favorite sessions from SMACC Chicago last year was the the debate between Chris Ho and Joe Bellezzo — both from Sharp Memorial Hospital in San Diego. Dr. Ho — on the resolution: ECPR (extracorporeal cardiopulmonary resuscitation) is a step to far. Dr. Ho took the affirmative side, arguing that ECPR (with is the same as ECMO) was not backed by any evidence of efficacy, horrendously expensive, resource-intensive, fraught with complications, and unethical. Dr. Bellezzo countered that all of his opponents objections were “bullshit.” The session was entertaining but also dead serious. To listen, click ...
Source: The Poison Review - February 14, 2016 Category: Toxicology Authors: Leon Tags: Medical Chris Ho ECMO ECPR extracorporeal cardiopulmonary resuscitation extracorporeal membrane oxygenation Joe Bellezzo saturday with smack SMACC Source Type: news
Severe bupropion overdose and ECMO: two great saves
ChaNaWiT/shutterstock.com
3.5 out of 5 stars
Two Cases of Refractory Cardiogenic Shock Secondary to Bupropion Successfully Treated with Veno-Arterial Extracorporeal Membrance Oxygenation. Heise CW et al. J Med Toxicol 2016 Feb 8 [Epub Ahead of Print]
Abstract
This awesome, exciting paper from Banner University Medical Center in Phoenix describes two teenagers with severe bupropion overdose who survived refractory cardiac arrest after veno-arterial extracorporeal membrane oxygenation (VA-ECMO):
Case 1: A 15-year-old girl was brought to hospital after ingesting up to 90 150-mg bupropion tablets. She had a seizure en route...
Source: The Poison Review - February 12, 2016 Category: Toxicology Authors: Leon Tags: Medical burpropion ECMO extracorporeal membrane oxygenation Source Type: news
Study: Nicotine Patch Works as Well as Chantix to Help Quit Smoking
This study confirms that FDA-approved medications are effective in helping smokers quit,” said Lee Westmaas, PhD, American Cancer Society director of tobacco control research. “Smokers should seriously consider using medications if they are finding it difficult to quit without any help. The most effective approach to quitting is using medications in combination with counseling such as from a quit-line.”RESOURCES: How to Quit Smoking Quit-smoking medicationsResearch shows that using a medication to help you quit smoking can double your chances of being successful.The US Food and Drug Administr...
Source: American Cancer Society :: News and Features - February 2, 2016 Category: Cancer & Oncology Tags: Smoking/Tobacco Source Type: news
Effects of Varenicline on alcohol enjoyment and consumption
Conclusion
Varenicline may affect enjoyment of drinking, but its potential to alter drinking behaviour is likely to be small.
Further Information
Conflicts of interest
PH and HM have received research funds and/or consultancy fees from manufacturers of smoking cessation medications. The remaining authors have no conflicts of interest to declare.
References
Childs, E., Roche, D. J. O., King, A. C. & De Wit, H. (2012). Varenicline Potentiates Alcohol-Induced Negative Subjective Responses and Offsets Impaired Eye Movements. Alcoholism: Clinical and Experimental Research, 36, 906-914.
Davis, T. J. & De Fiebre, C. M. (...
Source: Alcohol Research UK - December 16, 2015 Category: Addiction Authors: admin Tags: Alcohol Insights Source Type: news
Low-nicotine cigarettes may help determined smokers cut back
This study lasted only six weeks, so we’ll need longer trials to help us really understand whether low-nicotine cigarettes are a “safer” option for people who are determined to smoke (as many as one in five Americans is a current smoker). However, these findings do suggest that if the nicotine content in commercial cigarettes could be lowered, users would smoke less and be less likely to get “hooked,” which could mitigate the health risks associated with smoking.
For those who do want to cut out nicotine, there are good options that can help them meet the challenge. They come in many forms, from nicotine patches ...
Source: New Harvard Health Information - October 1, 2015 Category: Consumer Health News Authors: Mallika Marshall, MD Tags: Smoking cessation cigarettes low-nicotine cigarettes quit smoking Source Type: news
